Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients With Selected Intermediate-risk Factors: a Randomized Controlled Phase III Trials (ACCEPT Trial)

NCT05277688 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05277688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05277688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients With Selected Intermediate-risk Factors: a Randomized Controlled Phase III Trials (ACCEPT Trial)
Lead sponsor
Ruijin Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
March 15, 2022
Completion date
December 30, 2027
Enrollment
340 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer